Cargando…

Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014

OBJECTIVES: To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. DESIGN: Prospective cohort study. SETTING: Shenzhen, China. PARTICIPANTS: 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. INTE...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Peng, Tan, Jingguang, Ma, Wenzhe, Zheng, Hui, Lu, Yan, Wang, Ning, Peng, Zhihang, Yu, Rongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442238/
https://www.ncbi.nlm.nih.gov/pubmed/26002691
http://dx.doi.org/10.1136/bmjopen-2014-007508
_version_ 1782372874660610048
author Huang, Peng
Tan, Jingguang
Ma, Wenzhe
Zheng, Hui
Lu, Yan
Wang, Ning
Peng, Zhihang
Yu, Rongbin
author_facet Huang, Peng
Tan, Jingguang
Ma, Wenzhe
Zheng, Hui
Lu, Yan
Wang, Ning
Peng, Zhihang
Yu, Rongbin
author_sort Huang, Peng
collection PubMed
description OBJECTIVES: To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. DESIGN: Prospective cohort study. SETTING: Shenzhen, China. PARTICIPANTS: 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. INTERVENTION: Antiretroviral therapy according to the Chinese national treatment guidelines. OUTCOME MEASURES: Virological and immunological treatment failure rates. RESULTS: Of the 3099 patients surveyed, 2172 (70.1%) were included in the study. The median age was 33 years; 78.2% were male and 51.8% were infected through heterosexual contact. The median follow-up time was 31 months (IQR, 26–38). A total of 81 (3.7%) patients died, whereas 292 (13.4%) and 400 (18.4%) patients experienced virological and immunological failures, respectively. Adjusted Cox regression analysis indicated that baseline viral load (HR=2.19, 95% CI 1.52 to 4.48 for patients with a baseline viral load greater than or equal to 1 000 000 copies/mL compared to those with less than 10 000 copies/mL) and WHO stage (HR=4.16, 95% CI 2.01 to 10.57 for patients in WHO stage IV compared with those in stage I) were significantly associated with virological failure. The strongest risk factors for immunological treatment failure were a low CD4 cell count (HR=0.46, 95% CI 0.32 to 0.66 for patients with CD4 cell counts of 50–99 cells/mm(3) compared to those with less than 50 cells/mm(3)) and higher baseline WHO stage at treatment initiation (HR=2.15, 95% CI 1.38 to 3.34 for patients in WHO stage IV compared to those in stage I). CONCLUSIONS: Sustained virological and immunological outcomes show that patients have responded positively to long-term antiretroviral treatment with low mortality. This 10-year data study provides important information for clinicians and policymakers in the region as they begin to evaluate and plan for the future needs of their own rapidly expanding programmes.
format Online
Article
Text
id pubmed-4442238
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44422382015-05-28 Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014 Huang, Peng Tan, Jingguang Ma, Wenzhe Zheng, Hui Lu, Yan Wang, Ning Peng, Zhihang Yu, Rongbin BMJ Open HIV/AIDS OBJECTIVES: To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. DESIGN: Prospective cohort study. SETTING: Shenzhen, China. PARTICIPANTS: 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. INTERVENTION: Antiretroviral therapy according to the Chinese national treatment guidelines. OUTCOME MEASURES: Virological and immunological treatment failure rates. RESULTS: Of the 3099 patients surveyed, 2172 (70.1%) were included in the study. The median age was 33 years; 78.2% were male and 51.8% were infected through heterosexual contact. The median follow-up time was 31 months (IQR, 26–38). A total of 81 (3.7%) patients died, whereas 292 (13.4%) and 400 (18.4%) patients experienced virological and immunological failures, respectively. Adjusted Cox regression analysis indicated that baseline viral load (HR=2.19, 95% CI 1.52 to 4.48 for patients with a baseline viral load greater than or equal to 1 000 000 copies/mL compared to those with less than 10 000 copies/mL) and WHO stage (HR=4.16, 95% CI 2.01 to 10.57 for patients in WHO stage IV compared with those in stage I) were significantly associated with virological failure. The strongest risk factors for immunological treatment failure were a low CD4 cell count (HR=0.46, 95% CI 0.32 to 0.66 for patients with CD4 cell counts of 50–99 cells/mm(3) compared to those with less than 50 cells/mm(3)) and higher baseline WHO stage at treatment initiation (HR=2.15, 95% CI 1.38 to 3.34 for patients in WHO stage IV compared to those in stage I). CONCLUSIONS: Sustained virological and immunological outcomes show that patients have responded positively to long-term antiretroviral treatment with low mortality. This 10-year data study provides important information for clinicians and policymakers in the region as they begin to evaluate and plan for the future needs of their own rapidly expanding programmes. BMJ Publishing Group 2015-05-22 /pmc/articles/PMC4442238/ /pubmed/26002691 http://dx.doi.org/10.1136/bmjopen-2014-007508 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle HIV/AIDS
Huang, Peng
Tan, Jingguang
Ma, Wenzhe
Zheng, Hui
Lu, Yan
Wang, Ning
Peng, Zhihang
Yu, Rongbin
Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title_full Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title_fullStr Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title_full_unstemmed Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title_short Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014
title_sort outcomes of antiretroviral treatment in hiv-infected adults: a dynamic and observational cohort study in shenzhen, china, 2003–2014
topic HIV/AIDS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442238/
https://www.ncbi.nlm.nih.gov/pubmed/26002691
http://dx.doi.org/10.1136/bmjopen-2014-007508
work_keys_str_mv AT huangpeng outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT tanjingguang outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT mawenzhe outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT zhenghui outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT luyan outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT wangning outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT pengzhihang outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014
AT yurongbin outcomesofantiretroviraltreatmentinhivinfectedadultsadynamicandobservationalcohortstudyinshenzhenchina20032014